We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.
(AJMC.com) Apr 27, 2017 - At the 2017 Community Oncology Conference, participants discussed the impact of pharmacy benefit managers (PBMs) on oncology drug prices and patient access to much needed treatments.
(Urban Institute) Apr 23, 2017 - Medicare’s Oncology Care Model (OCM) is designed to incentivize providers to reduce unnecessary spending, improve care, and involve patients more closely in decisions about the use of chemotherapy.
(Yahoo! Finance) Apr 27, 2017 - New study finds low risk of contralateral breast cancer does not justify bilateral mastectomy for DCIS patients.
(AJMC.com) Apr 28, 2017 - Is rubber meeting the road with big data in cancer care? “No…rather, not yet,” Green said at the 2017 Community Oncology Conference, April 26-27, held at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.
(Medscape Medical News) Apr 28, 2017 - The risk for lymphedema in patients with breast cancer is not solely tied to surgery but is also associated with multiple other factors, including radiation therapy and chemotherapy, new research confirms.
(ESMO) Apr 28, 2017 - Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may have resulted in patients suffering unnecessarily from toxic side effects of the drugs.
(Medscape Medical News) Apr 27, 2017 - New position statement provides a template for physicians to prevent fractures in postmenopausal women receiving aromatase inhibitor (AI) therapy for breast cancer.
(PharmaTimes [UK]) Apr 28, 2017 - It is now looking likely that some patients with relapsed/refractory (R/R) Hodgkin lymphoma will be able to get routine access to Takeda’s Adcetris on the NHS after a major u-turn by cost regulators.
(VICC) Apr 27, 2017 - A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy.
(PharmaTimes [UK]) Apr 27, 2017 - Takeda has vowed to work with the National Institute for Health and Care Excellence to get NHS funding approved for its mutilple myeloma drug Ninlaro following an initial rejection by the cost watchdog.